ResMed Inc. (NYSE:RMD)
Stock Price:
$210.59
-0.19
(-0.09%)
Updated
Mar 23, 2023 08:00 PM GMT+0000
| Market Cap | 30.94B |
|---|---|
| Revenue | 3.76B |
| Gross Profit | 2.17B |
| Shares Out | 146.91M |
| EPS (ttm) | 5.5 |
| PE Ratio | 38.2544 |
| Forward PE | 32.7603 |
| Dividend Rate (ttm) | 1.7349 |
| Dividend Yield | 0.0082 |
| Trading Day | Mar 23 |
|---|---|
| Last Price | $210.59 |
| Previous Close | $210.78 |
| Change ($) | -0.19 |
| Change (%) | -0.09% |
| Day's Open | 211.43 |
| Day's Range | 209.13 - 214.13 |
| Day's Volume | 662.57K |
| 52 Week Range | 188.29 - 251.64 |
About ResMed Inc.
ResMed pioneers innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.
Its comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, the company improves quality of life, reduces the impact of chronic disease, and lowers costs for consumers and healthcare systems in more than 140 countries.
News
Quick info
Country
United States
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Employees
8,160
CEO
Michael Farrell
Address
9001 Spectrum Center Blvd
San Diego
California
92123-1438
San Diego
California
92123-1438
Phone
18587462400
Website
www.resmed.com
Ticker Symbol
RMD
Exchange
New York Stock Exchange
Reporting Currency
USD
ResMed Inc. income statements (2022) (USD)
| August 2022 | August 2022 | April 2022 | April 2022 | January 2022 | |
|---|---|---|---|---|---|
| Total Revenue | 0.91B | 0.91B | 864.50M | 864.50M | 894.87M |
| Cost of Revenue | 385.85M | 385.85M | 362.32M | 362.32M | 379.33M |
| Gross Profit | 528.89M | 528.89M | 502.18M | 502.18M | 515.55M |
| Research & Development | 64.32M | 64.32M | 66.80M | 66.80M | 62.51M |
| Selling General & Admin | 194.89M | 194.89M | 182.40M | 182.40M | 185.36M |
| Operating Expense | 661.90M | 661.90M | 632.86M | 632.86M | 648.08M |
| Operating Income | 252.84M | 252.84M | 231.64M | 231.64M | 246.80M |
| Other Income Expense Net | 0 | 0 | 0 | 0 | 0 |
| EBIT | 252.84M | 252.84M | 231.64M | 231.64M | 246.80M |
| Interest Income | 5.54M | 5.54M | 5.46M | 5.46M | 5.95M |
| Pretax Income | 238.09M | 238.09M | 226.32M | 226.32M | 237.29M |
| Income Tax | 43.03M | 43.03M | 47.31M | 47.31M | 35.54M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Net Income | 195.06M | 195.06M | 179.01M | 179.01M | 201.75M |
| Net Income Basic | 195.06M | 195.06M | 179.01M | 179.01M | 201.75M |
ResMed Inc. income statements (2021) (USD)
| October 2021 | October 2021 | August 2021 | April 2021 | January 2021 | |
|---|---|---|---|---|---|
| Total Revenue | 0.90B | 0.90B | 876.10M | 768.77M | 800.01M |
| Cost of Revenue | 386.67M | 386.67M | 374.35M | 310.59M | 326.36M |
| Gross Profit | 517.35M | 517.35M | 501.76M | 458.18M | 473.65M |
| Research & Development | 59.95M | 59.95M | 59.88M | 55.94M | 54.94M |
| Selling General & Admin | 176.72M | 176.72M | 181.48M | 160.45M | 169.47M |
| Operating Expense | 643.49M | 643.49M | 635.77M | 550.31M | 572.26M |
| Operating Income | 260.53M | 260.53M | 240.33M | 218.46M | 227.75M |
| Other Income Expense Net | 0 | 0 | 0 | 0 | 0 |
| EBIT | 260.53M | 260.53M | 240.33M | 218.46M | 227.75M |
| Interest Income | 5.36M | 5.36M | 5.29M | 5.82M | 5.79M |
| Pretax Income | 258.79M | 258.79M | 239.21M | 218.01M | 210.59M |
| Income Tax | 55.18M | 55.18M | 44.11M | 296.49M | 31.08M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Net Income | 203.61M | 203.61M | 195.10M | -78.48M | 179.51M |
| Net Income Basic | 203.61M | 203.61M | 195.10M | -78.48M | 179.51M |
ResMed Inc. income statements (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | 751.94M | 751.94M | 770.34M | 769.46M |
| Cost of Revenue | 301.30M | 321.53M | 329.19M | 328.07M |
| Gross Profit | 450.64M | 430.42M | 441.15M | 441.39M |
| Research & Development | 54.53M | 54.53M | 52.52M | 51.45M |
| Selling General & Admin | 158.99M | 158.99M | 165.39M | 172.44M |
| Operating Expense | 537.34M | 535.05M | 547.10M | 551.96M |
| Operating Income | 214.61M | 216.90M | 223.25M | 217.50M |
| Other Income Expense Net | 0 | -1.04M | -11.15M | -25.85M |
| EBIT | 214.61M | 216.90M | 223.25M | 217.50M |
| Interest Income | 6.73M | 6.73M | 9.20M | 9.97M |
| Pretax Income | 215.85M | 215.85M | 212.09M | 191.66M |
| Income Tax | 37.48M | 37.48M | 34.26M | 28.52M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 178.37M | 178.37M | 177.84M | 163.14M |
| Net Income Basic | 178.37M | 178.37M | 177.84M | 163.14M |
ResMed Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 736.16M | 681.06M | 704.96M | 662.23M |
| Cost of Revenue | 317.58M | 294.48M | 310.55M | 293.11M |
| Gross Profit | 418.57M | 386.58M | 394.41M | 369.12M |
| Research & Development | 49.94M | 48.03M | 51.14M | 47.61M |
| Selling General & Admin | 171.42M | 167.44M | 171.60M | 164.53M |
| Operating Expense | 538.95M | 509.95M | 533.29M | 505.25M |
| Operating Income | 197.21M | 171.10M | 171.68M | 156.98M |
| Other Income Expense Net | -18.46M | -20.52M | -75.91M | -19.05M |
| EBIT | 197.21M | 171.10M | 171.68M | 156.98M |
| Interest Income | 10.22M | 10.99M | 12.55M | 12.41M |
| Pretax Income | 178.75M | 150.59M | 95.76M | 137.93M |
| Income Tax | 18.20M | 30.44M | 26.96M | 32.51M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 160.55M | 120.15M | 68.80M | 105.42M |
| Net Income Basic | 160.55M | 120.15M | 68.80M | 105.42M |
ResMed Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 651.10M | 588.28M | 623.63M | 591.63M |
| Cost of Revenue | 283.21M | 258.05M | 272.77M | 259.01M |
| Gross Profit | 367.89M | 330.23M | 350.86M | 332.62M |
| Research & Development | 43.11M | 38.79M | 39.66M | 37.43M |
| Selling General & Admin | 161.58M | 147.30M | 156.81M | 147.89M |
| Operating Expense | 487.90M | 444.15M | 469.24M | 444.34M |
| Operating Income | 163.20M | 144.13M | 154.39M | 147.30M |
| Other Income Expense Net | -16.93M | -5.25M | -13.48M | -17.15M |
| EBIT | 163.20M | 144.13M | 154.39M | 147.30M |
| Interest Income | 7.49M | 3.71M | 5.48M | 7.72M |
| Pretax Income | 146.27M | 138.88M | 140.92M | 130.14M |
| Income Tax | 21.63M | 33.14M | 31.11M | 20.02M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 124.64M | 105.74M | 109.81M | 110.13M |
| Net Income Basic | 124.64M | 105.74M | 109.81M | 110.13M |
ResMed Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 601.27M | 523.66M | 556.69M |
| Cost of Revenue | 262.80M | 229.84M | 244.68M |
| Gross Profit | 338.48M | 293.82M | 312.01M |
| Research & Development | 40.64M | 37.42M | 36.71M |
| Selling General & Admin | 151.82M | 143.85M | 147.94M |
| Operating Expense | 455.26M | 411.10M | 429.33M |
| Operating Income | 146.02M | 112.56M | 127.36M |
| Other Income Expense Net | -4.25M | -4.07M | -5.74M |
| EBIT | 146.02M | 112.56M | 127.36M |
| Interest Income | 7.37M | 7.79M | 3.31M |
| Pretax Income | 141.77M | 108.49M | 121.62M |
| Income Tax | 132.24M | 22.36M | 20.01M |
| Minority Interest | 0 | 0 | 0 |
| Net Income | 9.53M | 86.13M | 101.61M |
| Net Income Basic | 9.53M | 86.13M | 101.61M |
ResMed Inc. balance sheet (2022) (USD)
| August 2022 | August 2022 | April 2022 | April 2022 | January 2022 | |
|---|---|---|---|---|---|
| Current Cash | 273.71M | 273.71M | 201.77M | 201.77M | 194.48M |
| Receivables | 575.95M | 575.95M | 508.58M | 508.58M | 526.04M |
| Inventory | 743.91M | 743.91M | 664.94M | 664.94M | 592.15M |
| Current Assets | 1.93B | 1.93B | 1.70B | 1.70B | 1.55B |
| Other Current Assets | 337.91M | 337.91M | 329.01M | 329.01M | 234.58M |
| Short Term Investments | 337.91M | 337.91M | 329.01M | 329.01M | 234.58M |
| Long Term Investments | 3.16B | 3.16B | 3.20B | 3.20B | 3.19B |
| Property/Plant Equipment | 498.18M | 498.18M | 513.25M | 513.25M | 477.78M |
| Good Will | N.A | N.A | N.A | N.A | N.A |
| Intangible Assets | 345.94M | 345.94M | 355.98M | 355.98M | 372.01M |
| Tangible Assets (Net) | 1.08B | 1.08B | 0.98B | 0.98B | 822.36M |
| Other Assets | 113.37M | 113.37M | 169.40M | 169.40M | 165.54M |
| Total Assets | 5.10B | 5.10B | 4.91B | 4.91B | 4.73B |
| Accounts Payable | 159.25M | 159.25M | 149.80M | 149.80M | 163.37M |
| Other Current Liabilities | 520.14M | 520.14M | 505.50M | 505.50M | 445.70M |
| Total Current Liabilities | 689.30M | 689.30M | 667.27M | 667.27M | 621.06M |
| Total Liabilities | 1.74B | 1.74B | 1.63B | 1.63B | 1.59B |
| Long Term Debt | 765.33M | 765.33M | 668.74M | 668.74M | 667.98M |
| Current Long Term Debt | 9.92M | 9.92M | 11.97M | 11.97M | 12M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 146.35M | 146.35M | 146.24M | 146.24M | 145.99M |
| Treasury Stock | -1.62B | -1.62B | -1.62B | -1.62B | -1.62B |
| Retained Earnings | 3.61B | 3.61B | 3.48B | 3.48B | 3.36B |
| Capital Surplus | N.A | N.A | N.A | N.A | N.A |
| Shareholder Equity | 3.36B | 3.36B | 3.28B | 3.28B | 3.15B |
| Other Liabilities | N.A | N.A | N.A | N.A | N.A |
ResMed Inc. balance sheet (2021) (USD)
| October 2021 | October 2021 | August 2021 | April 2021 | January 2021 | |
|---|---|---|---|---|---|
| Current Cash | 276.15M | 276.15M | 295.28M | 230.64M | 255.87M |
| Receivables | 575.55M | 575.55M | 614.29M | 525.01M | 509.36M |
| Inventory | 506.64M | 506.64M | 457.03M | 484.06M | 474.82M |
| Current Assets | 1.59B | 1.59B | 1.57B | 1.47B | 1.45B |
| Other Current Assets | 227.91M | 227.91M | 208.15M | 226.44M | 211.44M |
| Short Term Investments | 227.91M | 227.91M | 208.15M | 226.44M | 211.44M |
| Long Term Investments | 3.14B | 3.14B | 3.15B | 3.12B | 3.12B |
| Property/Plant Equipment | 467.34M | 467.34M | 463.49M | 455.11M | 459.47M |
| Good Will | N.A | N.A | N.A | N.A | N.A |
| Intangible Assets | 375.40M | 375.40M | 392.58M | 409.56M | 413M |
| Tangible Assets (Net) | 728.61M | 728.61M | 565.20M | 373.68M | 541.49M |
| Other Assets | 162.99M | 162.99M | 91.68M | 150.23M | 157.49M |
| Total Assets | 4.73B | 4.73B | 4.73B | 4.59B | 4.57B |
| Accounts Payable | 173.70M | 173.70M | 138.01M | 117.22M | 122.17M |
| Other Current Liabilities | 438.46M | 438.46M | 761.76M | 747.33M | 443.18M |
| Total Current Liabilities | 624.16M | 624.16M | 0.91B | 876.54M | 577.34M |
| Total Liabilities | 1.70B | 1.70B | 1.84B | 1.88B | 1.71B |
| Long Term Debt | 793.67M | 793.67M | 643.35M | 719.05M | 813.73M |
| Current Long Term Debt | 12M | 12M | 12M | 11.99M | 11.99M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 145.68M | 145.68M | 145.59M | 145.51M | 145.25M |
| Treasury Stock | -1.62B | -1.62B | -1.62B | -1.62B | -1.62B |
| Retained Earnings | 3.22B | 3.22B | 3.08B | 2.94B | 3.08B |
| Capital Surplus | N.A | N.A | N.A | N.A | N.A |
| Shareholder Equity | 3.03B | 3.03B | 2.89B | 2.71B | 2.86B |
| Other Liabilities | N.A | N.A | N.A | N.A | N.A |
ResMed Inc. balance sheet (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Current Cash | 421.41M | N.A | 463.16M | 352.86M |
| Receivables | 464.89M | 464.89M | 484.10M | 563.40M |
| Inventory | 478.01M | 478.01M | 416.92M | 358.77M |
| Current Assets | 1.54B | 1.54B | 1.52B | 1.47B |
| Other Current Assets | 178.30M | 178.30M | 159.29M | 194.72M |
| Short Term Investments | 178.30M | N.A | N.A | N.A |
| Long Term Investments | 3.08B | N.A | 44.14M | 50.12M |
| Property/Plant Equipment | 424.82M | 549.29M | 535.68M | 523.49M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 432.89M | N.A | 448.17M | 464.96M |
| Tangible Assets (Net) | 346.22M | 2.68B | -2.12B | -2.34B |
| Other Assets | 145.52M | 196.31M | 97.58M | 84.52M |
| Total Assets | 4.62B | 4.62B | 4.59B | 4.51B |
| Accounts Payable | 117.59M | 117.59M | 135.79M | 116.15M |
| Other Current Liabilities | 461.28M | 371.89M | 368.97M | 332.31M |
| Total Current Liabilities | 590.85M | 590.85M | 602.76M | 551.52M |
| Total Liabilities | 1.94B | 1.94B | 2.09B | 2.25B |
| Long Term Debt | 1.04B | 1.16B | 1.27B | 1.47B |
| Current Long Term Debt | 11.99M | N.A | 11.99M | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 1.59B | N.A | 144.89M | 144.66M |
| Treasury Stock | -1.62B | 1.62B | 1.62B | 1.62B |
| Retained Earnings | 2.95B | 2.95B | 2.83B | 2.71B |
| Capital Surplus | N.A | 1.59B | 1.57B | 1.53B |
| Shareholder Equity | 2.68B | 2.68B | 2.50B | 2.26B |
| Other Liabilities | N.A | N.A | N.A | N.A |
ResMed Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 204.10M | 172.15M | 147.13M | 146.51M |
| Receivables | 535.83M | 502.41M | 538.32M | 521.85M |
| Inventory | 377.78M | 357.03M | 349.64M | 319.93M |
| Current Assets | 1.30B | 1.16B | 1.15B | 1.10B |
| Other Current Assets | 182.78M | 129.50M | 110.28M | 114.41M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | 54.74M | 45.39M | 52.10M | 49.15M |
| Property/Plant Equipment | 505.11M | 464.62M | 387.46M | 382.50M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 480.86M | 496.85M | 521.95M | 516.45M |
| Tangible Assets (Net) | -2.32B | -2.42B | -2.49B | -2.68B |
| Other Assets | 104.02M | 91.23M | 94.28M | 72.76M |
| Total Assets | 4.35B | 4.15B | 4.11B | 4.10B |
| Accounts Payable | 114.32M | 109.74M | 115.73M | 124.47M |
| Other Current Liabilities | 310.80M | 318.21M | 355.03M | 273.42M |
| Total Current Liabilities | 500.05M | 550.46M | 555.99M | 462.97M |
| Total Liabilities | 2.10B | 2.04B | 2.04B | 2.08B |
| Long Term Debt | 1.37B | 1.27B | 1.26B | 1.32B |
| Current Long Term Debt | N.A | N.A | 11.99M | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 144.60M | 143.77M | 143.65M | 143.35M |
| Treasury Stock | 1.62B | 1.62B | 1.62B | 1.62B |
| Retained Earnings | 2.60B | 2.50B | 2.44B | 2.42B |
| Capital Surplus | 1.52B | 1.53B | 1.51B | 1.48B |
| Shareholder Equity | 2.26B | 2.12B | 2.07B | 2.02B |
| Other Liabilities | N.A | N.A | N.A | N.A |
ResMed Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 149.47M | 230.19M | 188.70M | 704.28M |
| Receivables | 477.19M | 463.74M | 483.68M | 498.43M |
| Inventory | 296.51M | 282.56M | 268.70M | 288.70M |
| Current Assets | 1.06B | 1.09B | 1.07B | 1.60B |
| Other Current Assets | 140.37M | 111.76M | 124.63M | 113M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | 62.86M | 41.23M | 41.23M | 41.15M |
| Property/Plant Equipment | 381.51M | 381.82M | 386.55M | 397.98M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 484.93M | 242.19M | 215.18M | 228.22M |
| Tangible Assets (Net) | -2.33B | -0.99B | -545.97M | -573.42M |
| Other Assets | 75.24M | 75.80M | 232.48M | 135.22M |
| Total Assets | 3.86B | 3.07B | 3.06B | 3.53B |
| Accounts Payable | 110.34M | 98.71M | 92.72M | 88.16M |
| Other Current Liabilities | 264.25M | 234.29M | 246.63M | 248.73M |
| Total Current Liabilities | 436.44M | 421.11M | 511.25M | 461.46M |
| Total Liabilities | 1.90B | 1.17B | 1B | 1.47B |
| Long Term Debt | 1.19B | 517.64M | 269.99M | 810M |
| Current Long Term Debt | N.A | N.A | 11.47M | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 143.28M | 142.49M | 142.68M | 142.72M |
| Treasury Stock | 1.62B | 1.62B | 1.60B | 1.57B |
| Retained Earnings | 2.37B | 2.30B | 2.43B | 2.37B |
| Capital Surplus | 1.46B | 1.46B | 1.45B | 1.42B |
| Shareholder Equity | 1.96B | 1.90B | 2.06B | 2.07B |
| Other Liabilities | N.A | N.A | N.A | N.A |
ResMed Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 858.90M | 811.10M | 821.94M |
| Receivables | 482.93M | 431.35M | 450.53M |
| Inventory | 296.06M | 300.47M | 268.32M |
| Current Assets | 1.75B | 1.66B | 1.64B |
| Other Current Assets | 116.45M | 115.02M | 103.22M |
| Short Term Investments | N.A | N.A | N.A |
| Long Term Investments | 39.80M | 40.59M | 38.32M |
| Property/Plant Equipment | 401.54M | 400.80M | 394.24M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 240.03M | 251.03M | 261.80M |
| Tangible Assets (Net) | -612.29M | -572.97M | -640.51M |
| Other Assets | 2.26M | 3.12M | 3.74M |
| Total Assets | 3.56B | 3.49B | 3.47B |
| Accounts Payable | 78.35M | 85.08M | 92.76M |
| Other Current Liabilities | 242.65M | 232.52M | 238.21M |
| Total Current Liabilities | 1.36B | 351.59M | 360.13M |
| Total Liabilities | 1.54B | 1.44B | 1.51B |
| Long Term Debt | N.A | 1.02B | 1.08B |
| Current Long Term Debt | 1.02B | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 142.89M | 142.26M | 142.17M |
| Treasury Stock | 1.56B | 1.55B | 1.55B |
| Retained Earnings | 2.31B | 2.35B | 2.32B |
| Capital Surplus | 1.41B | 1.40B | 1.38B |
| Shareholder Equity | 2.02B | 2.05B | 1.96B |
| Other Liabilities | N.A | N.A | N.A |
ResMed Inc. cash flow (2023) (USD)
| January 2023 | |
|---|---|
| Net Income | 224.91M |
| Depreciation | 45.54M |
| Changes in Receivables | 672.27M |
| Changes in Inventories | 0.99B |
| Cash Change | 253.20M |
| Cash Flow | 128.64M |
| Capital Expenditures | -27.35M |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | -1.03B |
| Dividends Paid | N.A |
| Net Borrowings | 1.14B |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | 0.93B |
| Exchange Rate Effect | N.A |
ResMed Inc. cash flow (2022) (USD)
| August 2022 | April 2022 | |
|---|---|---|
| Net Income | 195.06M | 179.01M |
| Depreciation | 45.01M | 51.61M |
| Changes in Receivables | 575.95M | 508.58M |
| Changes in Inventories | 743.91M | 664.94M |
| Cash Change | 273.71M | 201.77M |
| Cash Flow | 79.49M | 117.44M |
| Capital Expenditures | -49.84M | -48.45M |
| Investments | N.A | N.A |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | -55.24M | -49.5M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | 163.62M | 149.93M |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | 57.50M | -60.86M |
| Exchange Rate Effect | N.A | N.A |
ResMed Inc. cash flow (2021) (USD)
| October 2021 | |
|---|---|
| Net Income | 203.61M |
| Depreciation | 47.62M |
| Changes in Receivables | 575.55M |
| Changes in Inventories | 506.64M |
| Cash Change | 276.15M |
| Cash Flow | -65.66M |
| Capital Expenditures | -27.34M |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | -41.87M |
| Dividends Paid | N.A |
| Net Borrowings | 301.61M |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | 92.97M |
| Exchange Rate Effect | N.A |
ResMed Inc. cash flow (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Net Income | 178.37M | 178.37M | 177.84M | 163.14M |
| Depreciation | 39.47M | 49.89M | 45.51M | 46.47M |
| Changes in Receivables | -9.75M | 19.20M | 79.31M | -27.57M |
| Changes in Inventories | 61.09M | -52.4M | -47.32M | 5.73M |
| Cash Change | -41.74M | -41.74M | 110.30M | 148.77M |
| Cash Flow | 144M | 144M | 330.27M | 239.70M |
| Capital Expenditures | -13.5M | -18.74M | -21.19M | -32.11M |
| Investments | N.A | -8.2M | N.A | -9.78M |
| Investing Activity (other) | N.A | N.A | 17.78M | -32.18M |
| Total Investing Cash Flows | -22.11M | -22.11M | -3.41M | -99.61M |
| Dividends Paid | N.A | -56.51M | -56.48M | -56.41M |
| Net Borrowings | 456.71M | -120M | -201M | 77M |
| Other Financing Cash Flows | N.A | 227K | -0.96M | -4.02M |
| Cash Flow Financing | -175.26M | -175.26M | -236.37M | 18.39M |
| Exchange Rate Effect | N.A | 11.63M | 19.81M | -9.71M |
ResMed Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | 160.55M | 120.15M | 68.80M | 105.42M |
| Depreciation | 45.48M | 43.92M | 42.59M | 41.75M |
| Changes in Receivables | -33.42M | 35.91M | -16.47M | -44.66M |
| Changes in Inventories | -14.09M | -14.2M | -29.19M | -24.43M |
| Cash Change | 31.94M | 25.03M | 615K | -2.96M |
| Cash Flow | 69.93M | 162.36M | 141.82M | 139.65M |
| Capital Expenditures | -27.9M | -24.74M | -24.28M | -17M |
| Investments | -19.1M | -2.74M | -15.63M | -3.13M |
| Investing Activity (other) | 5.74M | -5.74M | -264K | 3.13M |
| Total Investing Cash Flows | -43.62M | -33.22M | -43.89M | -225.41M |
| Dividends Paid | -56.15M | -56.05M | -53.12M | -53.03M |
| Net Borrowings | 78.99M | -49M | -65.35M | 134.40M |
| Other Financing Cash Flows | -40.77M | -628K | -485K | -758K |
| Cash Flow Financing | 764K | -100.07M | -97.58M | 83.18M |
| Exchange Rate Effect | 4.86M | -4.04M | 260K | -377K |
ResMed Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | 124.64M | 105.74M | 109.81M | 110.13M |
| Depreciation | 36.03M | 30.42M | 31.70M | 29.31M |
| Changes in Receivables | -13.45M | 19.94M | 14.74M | -15.49M |
| Changes in Inventories | -14.91M | -15.66M | 12.64M | 9.61M |
| Cash Change | -80.72M | 41.49M | -515.58M | -154.62M |
| Cash Flow | 129.47M | 48.12M | 129.42M | 149.08M |
| Capital Expenditures | -20.46M | -15.61M | -19.75M | -15.08M |
| Investments | -25.5M | -2.47M | -8.05M | -2.72M |
| Investing Activity (other) | 551K | -3.68M | -10.3M | -1.34M |
| Total Investing Cash Flows | -658.22M | -148.19M | -38.53M | -19.62M |
| Dividends Paid | -52.77M | -52.79M | -49.97M | -49.97M |
| Net Borrowings | 521.57M | 216.87M | -526.24M | -210M |
| Other Financing Cash Flows | -27.53M | -240K | -281K | -205K |
| Cash Flow Financing | 450.21M | 144.82M | -588.67M | -276.52M |
| Exchange Rate Effect | -2.18M | -3.27M | -17.8M | -7.56M |
ResMed Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | 9.53M | 86.13M | 101.61M |
| Depreciation | 29.37M | 29.57M | 28.17M |
| Changes in Receivables | -51.58M | 19.18M | -36.92M |
| Changes in Inventories | 6.18M | -26.94M | -3.45M |
| Cash Change | 47.80M | -10.83M | -5.38M |
| Cash Flow | 132.55M | 93.98M | 140.31M |
| Capital Expenditures | -18.35M | -18.27M | -20.64M |
| Investments | -500K | -3.23M | N.A |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -28.26M | -15.42M | -31.28M |
| Dividends Paid | -49.86M | -49.7M | -46.8M |
| Net Borrowings | N.A | -60M | -90M |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | -55.42M | -106.08M | -121.89M |
| Exchange Rate Effect | -1.08M | 16.69M | 7.49M |
ResMed Inc. dividends (USD)
| Ex date | Payment date | Record date | Declared date | Amount | Description | Frequency |
|---|---|---|---|---|---|---|
| 09-11-2022 | 15-12-2022 | 10-11-2022 | N.A | 0.44 | Ordinary Shares | Quarterly |
| 17-08-2022 | 22-09-2022 | 18-08-2022 | N.A | 0.44 | Ordinary Shares | Quarterly |
| 09-11-2021 | 16-12-2021 | 11-11-2021 | N.A | 0.42 | Ordinary Shares | Quarterly |
| 10-11-2020 | 17-12-2020 | 12-11-2020 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 19-08-2020 | 24-09-2020 | 20-08-2020 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 13-05-2020 | 18-06-2020 | 14-05-2020 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 12-02-2020 | 19-03-2020 | 13-02-2020 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 06-11-2019 | 12-12-2019 | 07-11-2019 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 14-08-2019 | 19-09-2019 | 15-08-2019 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 08-05-2019 | 13-06-2019 | 09-05-2019 | N.A | 0.37 | Ordinary Shares | Quarterly |
| 06-02-2019 | 14-03-2019 | 07-02-2019 | N.A | 0.37 | Ordinary Shares | Quarterly |
| 07-11-2018 | 13-12-2018 | 08-11-2018 | N.A | 0.37 | Ordinary Shares | Quarterly |
| 15-08-2018 | 20-09-2018 | 16-08-2018 | N.A | 0.37 | Ordinary Shares | Quarterly |
| 09-05-2018 | 14-06-2018 | 10-05-2018 | N.A | 0.35 | Ordinary Shares | Quarterly |
| 07-02-2018 | 15-03-2018 | 08-02-2018 | N.A | 0.35 | Ordinary Shares | Quarterly |
| 08-11-2017 | 14-12-2017 | 09-11-2017 | N.A | 0.35 | Ordinary Shares | Quarterly |
| 15-08-2017 | 21-09-2017 | 17-08-2017 | N.A | 0.35 | Ordinary Shares | Quarterly |
| 09-05-2017 | 15-06-2017 | 11-05-2017 | N.A | 0.33 | Ordinary Shares | Quarterly |
| 07-02-2017 | 16-03-2017 | 09-02-2017 | N.A | 0.33 | Ordinary Shares | Quarterly |
| 08-11-2016 | 15-12-2016 | 10-11-2016 | N.A | 0.33 | Ordinary Shares | Quarterly |
| 16-08-2016 | 22-09-2016 | 18-08-2016 | N.A | 0.33 | Ordinary Shares | Quarterly |
| 17-05-2016 | 16-06-2016 | 19-05-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 09-02-2016 | 17-03-2016 | 11-02-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 17-11-2015 | 17-12-2015 | 19-11-2015 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 18-08-2015 | 17-09-2015 | 20-08-2015 | N.A | 0.30 | Ordinary Shares | Quarterly |
Total Valuation
Resmed Inc. has a market cap or net worth of $30.94 billion. The enterprise value is $32.51 billion.
Market Cap
30.94B
Enterprise Value
32.51B
Important Dates
Earnings Date
Apr 27, 2023
Ex-Dividend Date
n.a
Share Statistics
Resmed Inc. has 146.91 million shares outstanding.
Shares Outstanding
146.91M
Float
n.a
Valuation Ratios
The trailing PE ratio is 38.2544 and the forward PE ratio is 32.7603. Resmed Inc.'s PEG ratio is 0.7000.
PE Ratio
38.2544
Forward PE
32.7603
PS Ratio
8.2300
PB Ratio
8.2800
PEG Ratio
0.7000
Stock Price Statistics
The stock price has increased by 0.0147%. The beta is 0.8561, so Resmed Inc.'s price volatility has been lower than the market average.
Beta (1Y)
0.8561
52-Week Price Change
+0.0147%
50-Day Moving Average
214.48
200-Day Moving Average
218.79
Average Volume (30 Days)
656.03K
Income Statement
In the last 12 months, Resmed Inc. had revenue of $3.76 billion and earned $2.17 billion in profits. Earnings per share was $5.5.
Revenue
3.76B
Gross Profit
2.17B
EBITDA
1.11B
Earnings per Share
5.5
About
Ticker Symbol
RMD
Reporting Currency
USD
Key Executives
Darkin Donald
Sr. Vice President
Relser Anne
President - ResMed Europe
Gallahue Kieran
Chief Executive Officer
PENDARVIS DAVID
Sr. VP, General Counsel
Douglas Robert Andrew
COO Asia Pacific
EISEN PAUL
Sr. V P, Asia Pacific
Ghoshal Kaushik
President, SaaS Business
FARRELL PETER C
Chairman of the Board